Reinventing Glial Cell Models & Optimizing Neuroinflammatory Biomarker Discovery & Development
With increasing prioritization for neuroscience discovery, huge biopharma is investing in expanding its departments, focusing on glial biology, neuroinflammatory biomarkers, and optimizing various approaches to target the likes of LRKK2, TREM2, and more. Therefore, there is a great amount of novel and promising research to be discussed in 2023.
Uniting 100+ neuroinflammation and neuroimmunology experts across all neurological indications, including AD, PD, ALS, and MS, the 5th Annual Neuroimmunology Drug Development meeting will return to Boston to host discovery, preclinical, translational, and clinical experts from the likes of Genentech, Muna Therapeutics, Biogen, Janssen, Bristol Myers Squibb, Sanofi, Takeda, and Roche.
With new speakers from the hottest biopharma in neuroimmunology delivering, a comprehensive program of pioneering and cutting-edge content, don’t miss your crucial chance to join this niche audience of innovators with a shared desire to explore strategy, creation, and implementation of research, biomarker, and clinical hypothesis testing in neuroimmunology.
Your 30+ World-Class Speaker Faculty Includes:
Biomarker Experimental Medicine Leader
Senior Director - Scientific, Preclinical Sciences & Neuroscience
Bristol Myers Squibb
Head of Translational Medicine
Group Director - Medical & Biomarker Development
Previously Attending Companies Include:
Hear Why Your Industry Peers are Excited to Return:
“High quality speakers and organization - a must-attend meeting for drug developers in neuroimmunology.” Johan Luthman, Executive Vice President & Head of Research & Development, Lundbeck”
“Timely, relevant, high-quality topics discussed by leading researchers in an intimate setting.” - Scott Shandler, Founder & Chief Executive Officer, Longevity Biotech
“Very focused summit, good learning opportunity” - Lina Wang, Associate Principal Scientist, Discovery Biology, Merck & Co"
“Quality, intimate and insightful meeting” - Henry Wu, Director, Clinical Development Global Medical, Biogen"